MRNA
NASDAQ · Biotechnology
Moderna Inc
$51.34
+0.06 (+0.12%)
Financial Highlights (FY 2026)
Revenue
2.37B
Net Income
-3,435,222,270
Gross Margin
55.3%
Profit Margin
-145.2%
Rev Growth
-53.4%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 55.3% | 55.3% | 45.8% | 45.8% |
| Operating Margin | -158.1% | -142.3% | -12.3% | -14.0% |
| Profit Margin | -145.2% | -137.9% | -12.8% | -13.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.37B | 5.08B | 2.23B | 2.33B |
| Gross Profit | 1.31B | 2.81B | 1.02B | 1.07B |
| Operating Income | -3,742,016,868 | -7,233,280,028 | -274,760,049 | -327,869,077 |
| Net Income | -3,435,222,270 | -6,640,249,233 | -285,156,561 | -311,574,543 |
| Gross Margin | 55.3% | 55.3% | 45.8% | 45.8% |
| Operating Margin | -158.1% | -142.3% | -12.3% | -14.0% |
| Profit Margin | -145.2% | -137.9% | -12.8% | -13.4% |
| Rev Growth | -53.4% | -53.4% | +3.0% | +13.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 639.45M | 639.45M | 2.72B | 2.91B |
| Total Equity | 9.07B | 9.07B | 5.26B | 5.64B |
| D/E Ratio | 0.07 | 0.07 | 0.52 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -3,490,009,673 | -7,120,938,980 | -355,384,473 | -379,950,378 |
| Free Cash Flow | — | — | -237,052,091 | -246,991,527 |